

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

PerCP/Cyanine5.5 anti-mouse CD3

RRID:AB_1595492

Type: Antibody

Proper Citation

BioLegend Cat# 100218, RRID:AB_1595492

Antibody Information

URL: http://antibodyregistry.org/AB_1595492

Proper Citation: BioLegend Cat# 100218, RRID:AB_1595492

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_1595492

Vendor: BioLegend

Catalog Number: 100218

Alternative Catalog Numbers: 100217

Record Creation Time: 20250819T220327+0000

Record Last Update: 20250820T005759+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-mouse CD3.

No alerts have been found for PerCP/Cyanine5.5 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 61 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Han J, et al. (2026) A chemical agonist and the Golgi-resident lipid PI4P activate STING by inducing transmembrane helix rearrangement. *Immunity*, 59(1), 34.

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. *Cell reports. Medicine*, 102532.

Qiao S, et al. (2026) Microbiota utilization of intestinal amino acids modulates cancer progression and anticancer immunity. *Cell host & microbe*, 34(1), 18.

Yeat NY, et al. (2025) Bro1 proteins determine tumor immune evasion and metastasis by controlling secretion or degradation of multivesicular bodies. *Developmental cell*, 60(15), 2114.

Li T, et al. (2025) Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation. *Molecular cell*, 85(13), 2517.

Yang Z, et al. (2025) A mosaic H3 subtype live attenuated influenza vaccine elicits broad immune responses to influenza A viruses. *Vaccine*, 65, 127776.

Wang Y, et al. (2025) Activation of stimulator of interferon genes (STING) and inhibition of vascular endothelial growth factor receptor (VEGFR) by telatinib induce antitumor activity. *The Journal of biological chemistry*, 111038.

Dai Z, et al. (2025) Single-cell analysis of temporal immune cell dynamics in alopecia areata reveals a causal role for clonally expanded CD8+ T cells in disease. *Cell reports*, 44(7), 115798.

Han P, et al. (2025) Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy. *Cell metabolism*, 37(12), 2438.

Gonzalez-Garcia P, et al. (2025) Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting. *Molecular oncology*.

Stomper J, et al. (2025) Sex differences in DNMT3A-mutant clonal hematopoiesis and the effects of estrogen. *Cell reports*, 44(4), 115494.

Gao C, et al. (2025) Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure. *Cell reports. Medicine*, 6(5), 102092.

Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. *Cell reports. Medicine*, 6(10), 102413.

Vasquez JH, et al. (2025) Somatic Miwi2 modulates mitochondrial function in airway multiciliated cells and exacerbates influenza pathogenesis. *iScience*, 28(4), 112291.

Chakraborty S, et al. (2025) Sialylated IgG induces the transcription factor REST in alveolar macrophages to protect against lung inflammation and severe influenza disease. *Immunity*, 58(1), 182.

Janus-Bell E, et al. (2025) Depletion of all platelet integrins impacts hemostasis, thrombosis, and tumor metastasis. *iScience*, 28(9), 113250.

Wei Q, et al. (2025) Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3. *iScience*, 28(3), 111931.

Jin WB, et al. (2025) Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity. *Cell*, 188(9), 2336.

Yang Z, et al. (2025) Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity. *Science advances*, 11(29), eadw0797.

Yamane K, et al. (2025) ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity. *International journal of molecular sciences*, 26(7).